Analytical Data
-
Gene name
gABRa2
- Application
-
Alternative Names
GABA(A) receptor subunit alpha-2
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P47869
-
Expression Region
Phe42~Ile250
-
Molecular Weight
64kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The GABRA2 gene encodes the alpha-2 subunit of the gamma-aminobutyric acid (GABA) receptor, which is a critical inhibitory neurotransmitter receptor in the central nervous system. Research on GABRA2 has gained prominence due to its association with various neurological and psychiatric disorders, including anxiety, depression, and alcohol dependence. Understanding the structure and function of the GABRA2 recombinant protein is essential for elucidating its role in synaptic transmission and its potential implications in drug development. Recombinant protein studies allow for detailed investigations into the biophysical properties, ligand-binding characteristics, and the impact of specific mutations on receptor function. Furthermore, GABRA2's involvement in neuropharmacology makes it a target for therapeutic interventions aimed at modulating GABAergic signaling. By producing and characterizing GABRA2 recombinant proteins, researchers aim to uncover mechanisms underlying its function, pave the way for the development of new pharmacological agents, and ultimately contribute to better treatment strategies for disorders linked to GABAergic dysfunction.
